Comparison of the effects of bazedoxifene and eldecalcitol on the health screening results of postmenopausal women

Comparison of the effects of bazedoxifene and eldecalcitol on the health screening results of postmenopausal women - Comparison of the effects of bazedoxifene and eldecalcitol on the health screening results of postmenopausal women

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023659

Enrollment

200

Registered

2016-09-01

Start date

2016-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postmenopausal osteoporosis

Interventions

12-month treatment with 20 mg of bazedoxifene 12-month treatment with 0.75mcg of eldecalcitol

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: patients who need medical treatment of osteoporosis, with one or less spinal fractures

Exclusion criteria

Exclusion criteria: (1) past history of arterial/venous thromboembolism (2) past history of urollithiasis (3) use of aromatase inhibitors for the adjuvant treatment of breast cancer (4) renal dysfunction with eGFR less than 50 ml/min

Design outcomes

Primary

Measure	Time frame
changes in lumbar spine/hip BMD after 12 months of treatment	—

Secondary

Measure	Time frame
changes in bone metabolism markers, health-related QOL, and the results of a health screening program after 12 months of treatment	—

Countries

Japan

Contacts

Public ContactMasakazu Terauchi

Tokyo Medical and Dental University Department of Women's Health

teragyne@tmd.ac.jp03-5803-4605

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026